{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T16:18:48Z","timestamp":1792167528200,"version":"4.4.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.modpat.2026.101071","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T23:39:24Z","timestamp":1787701164000},"page":"101071","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Integrated Bulk and Spatial Proteomics of Castleman Disease: Molecular Signatures Across Subtypes and Compartmentalized Pathogenic Networks in Idiopathic Multicentric Castleman disease (iMCD)\u2013Thrombocytopenia, Anasarca, Fever, Reticulin Fibrosis\/Renal Dysfunction, and Organomegaly (TAFRO)"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9553-4739","authenticated-orcid":false,"given":"Shuang","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuqi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghua","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.modpat.2026.101071_bib1","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41572-021-00317-7","article-title":"Castleman disease","volume":"7","author":"Carbone","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"10.1016\/j.modpat.2026.101071_bib2","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70329","article-title":"Is \u201csevere\u201d idiopathic multicentric Castleman disease (iMCD)-idiopathic plasmacytic lymphadenopathy (IPL) really severe?","volume":"10","author":"Li","year":"2026","journal-title":"Hemasphere"},{"issue":"5","key":"10.1016\/j.modpat.2026.101071_bib3","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1111\/bjh.19334","article-title":"Idiopathic multicentric Castleman disease (iMCD)-idiopathic plasmacytic lymphadenopathy: a distinct subtype of iMCD-not otherwise specified with different clinical features and better survival","volume":"204","author":"Gao","year":"2024","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.modpat.2026.101071_bib4","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1002\/ajh.26292","article-title":"Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease","volume":"96","author":"Nishimura","year":"2021","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.modpat.2026.101071_bib5","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/ajh.24242","article-title":"Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease","volume":"91","author":"Iwaki","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.modpat.2026.101071_bib6","article-title":"A national, multicenter, retrospective study of Castleman disease in China implementing CDCN criteria","volume":"34","author":"Zhang","year":"2023","journal-title":"Lancet Reg Health West Pac"},{"issue":"7","key":"10.1016\/j.modpat.2026.101071_bib7","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.3324\/haematol.2023.283603","article-title":"Longitudinal, natural history study reveals the disease burden of idiopathic multicentric Castleman disease","volume":"109","author":"Bustamante","year":"2024","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.modpat.2026.101071_bib8","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/s12276-021-00649-0","article-title":"Interplay between interleukin-6 signaling and the vascular endothelium in cytokine storms","volume":"53","author":"Kang","year":"2021","journal-title":"Exp Mol Med"},{"issue":"23","key":"10.1016\/j.modpat.2026.101071_bib9","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMra2026131","article-title":"Cytokine storm","volume":"383","author":"Fajgenbaum","year":"2020","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.modpat.2026.101071_bib10","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1200\/JCO.2009.27.2377","article-title":"Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman disease","volume":"28","author":"van Rhee","year":"2010","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.modpat.2026.101071_bib11","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S1470-2045(14)70319-5","article-title":"Siltuximab for multicentric Castleman disease: a randomised, double-blind, placebo-controlled trial","volume":"15","author":"van Rhee","year":"2014","journal-title":"Lancet Oncol"},{"issue":"20","key":"10.1016\/j.modpat.2026.101071_bib12","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1182\/blood-2018-07-862334","article-title":"International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease","volume":"132","author":"van Rhee","year":"2018","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.modpat.2026.101071_bib13","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/ejh.13702","article-title":"Novel somatic alterations in unicentric and idiopathic multicentric Castleman disease","volume":"107","author":"Goodman","year":"2021","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.modpat.2026.101071_bib14","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/cei.13632","article-title":"Mediterranean fever gene variants modify clinical phenotypes of idiopathic multi-centric Castleman disease","volume":"206","author":"Endo","year":"2021","journal-title":"Clin Exp Immunol"},{"issue":"5","key":"10.1016\/j.modpat.2026.101071_bib15","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1111\/bjh.16330","article-title":"Whole-exome sequencing identifies novel somatic alterations associated with outcomes in idiopathic multicentric Castleman disease","volume":"188","author":"You","year":"2020","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.modpat.2026.101071_bib16","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/s41375-018-0323-6","article-title":"Recurrent PDGFRB mutations in unicentric Castleman disease","volume":"33","author":"Li","year":"2019","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.modpat.2026.101071_bib17","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1182\/bloodadvances.2017009654","article-title":"Next-generation sequencing of idiopathic multicentric and unicentric Castleman disease and follicular dendritic cell sarcomas","volume":"2","author":"Nagy","year":"2018","journal-title":"Blood Adv"},{"issue":"21","key":"10.1016\/j.modpat.2026.101071_bib18","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1182\/bloodadvances.2018023911","article-title":"A novel FAS mutation with variable expressivity in a family with unicentric and idiopathic multicentric Castleman disease","volume":"2","author":"Baker","year":"2018","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.modpat.2026.101071_bib19","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/modpathol.2013.202","article-title":"Monoclonality and cytogenetic abnormalities in hyaline vascular Castleman disease","volume":"27","author":"Chang","year":"2014","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.modpat.2026.101071_bib20","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3324\/haematol.2021.280370","article-title":"The lymph node transcriptome of unicentric and idiopathic multicentric Castleman disease","volume":"108","author":"Horna","year":"2023","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.modpat.2026.101071_bib21","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41379-021-00950-3","article-title":"Transcriptome and unique cytokine microenvironment of Castleman disease","volume":"35","author":"Wing","year":"2022","journal-title":"Mod Pathol"},{"issue":"7","key":"10.1016\/j.modpat.2026.101071_bib22","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/ajh.25123","article-title":"Plasma proteomics identifies a \u2018chemokine storm\u2019 in idiopathic multicentric Castleman disease","volume":"93","author":"Pierson","year":"2018","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.modpat.2026.101071_bib23","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1056\/NEJMc2412494","article-title":"Identifying and targeting TNF signaling in idiopathic multicentric Castleman disease","volume":"392","author":"Mumau","year":"2025","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.modpat.2026.101071_bib24","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1186\/s12967-025-06456-9","article-title":"Spatial transcriptomics study of Castleman disease","volume":"23","author":"Chen","year":"2025","journal-title":"J Transl Med"},{"issue":"9","key":"10.1016\/j.modpat.2026.101071_bib25","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/s41577-020-0281-x","article-title":"Lymphatic endothelial cells of the lymph node","volume":"20","author":"Jalkanen","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.modpat.2026.101071_bib26","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3389\/fimmu.2017.00045","article-title":"High endothelial venules and other blood vessels: critical regulators of lymphoid organ development and function","volume":"8","author":"Ager","year":"2017","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.modpat.2026.101071_bib27","doi-asserted-by":"crossref","first-page":"6009","DOI":"10.1038\/s41467-025-61214-1","article-title":"Spatial and single-cell mapping of Castleman disease reveals key stromal cell types and cytokine pathways","volume":"16","author":"Smith","year":"2025","journal-title":"Nat Commun"},{"issue":"18","key":"10.1016\/j.modpat.2026.101071_bib28","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1182\/blood.2023021992","article-title":"Single-cell landscape of idiopathic multicentric Castleman disease in identical twins","volume":"143","author":"Chan","year":"2024","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.modpat.2026.101071_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110955","article-title":"Spatial region-resolved proteome map reveals mechanism of COVID-19-associated heart injury","volume":"39","author":"Leng","year":"2022","journal-title":"Cell Rep"},{"issue":"6","key":"10.1016\/j.modpat.2026.101071_bib30","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.3390\/biomedicines12061328","article-title":"Increase in vascular endothelial growth factor (VEGF) expression and the pathogenesis of iMCD-TAFRO","volume":"12","author":"Srkalovic","year":"2024","journal-title":"Biomedicines"},{"issue":"9","key":"10.1016\/j.modpat.2026.101071_bib31","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.it.2021.07.003","article-title":"Communication, construction, and fluid control: lymphoid organ fibroblastic reticular cell and conduit networks","volume":"42","author":"Acton","year":"2021","journal-title":"Trends Immunol"},{"issue":"5","key":"10.1016\/j.modpat.2026.101071_bib32","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41577-023-00965-8","article-title":"Same yet different\u2014how lymph node heterogeneity affects immune responses","volume":"24","author":"Cruz de Casas","year":"2024","journal-title":"Nat Rev Immunol"},{"issue":"8","key":"10.1016\/j.modpat.2026.101071_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2025.100782","article-title":"The involvement of PI3K-Akt signaling in the clinical and pathological findings of idiopathic multicentric Castleman disease-thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly and not otherwise specified subtypes","volume":"38","author":"Haratake","year":"2025","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1016\/j.modpat.2026.101071_bib34","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41569-023-00913-y","article-title":"The role of cardiac pericytes in health and disease: therapeutic targets for myocardial infarction","volume":"21","author":"Avolio","year":"2024","journal-title":"Nat Rev Cardiol"},{"issue":"11","key":"10.1016\/j.modpat.2026.101071_bib35","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/s41581-023-00752-7","article-title":"Role of perivascular cells in kidney homeostasis, inflammation, repair, and fibrosis","volume":"19","author":"Tanaka","year":"2023","journal-title":"Nat Rev Nephrol"},{"issue":"4","key":"10.1016\/j.modpat.2026.101071_bib36","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1177\/0271678X221145092","article-title":"PDGFRbeta-positive cell-mediated poststroke remodeling of fibronectin and laminin alpha2 for tissue repair and functional recovery","volume":"43","author":"Shibahara","year":"2023","journal-title":"J Cereb Blood Flow Metab"},{"issue":"5","key":"10.1016\/j.modpat.2026.101071_bib37","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s12276-022-00778-0","article-title":"TGF-beta promotes pericyte-myofibroblast transition in subretinal fibrosis through the Smad2\/3 and Akt\/mTOR pathways","volume":"54","author":"Zhao","year":"2022","journal-title":"Exp Mol Med"},{"issue":"11","key":"10.1016\/j.modpat.2026.101071_bib38","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1111\/jcmm.17251","article-title":"Increased mTORC2 pathway activation in lymph nodes of iMCD-TAFRO","volume":"26","author":"Phillips","year":"2022","journal-title":"J Cell Mol Med"},{"issue":"10","key":"10.1016\/j.modpat.2026.101071_bib39","doi-asserted-by":"crossref","first-page":"4451","DOI":"10.1172\/JCI126091","article-title":"Identifying and targeting pathogenic PI3K\/AKT\/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease","volume":"129","author":"Fajgenbaum","year":"2019","journal-title":"J Clin Invest"},{"issue":"9","key":"10.1016\/j.modpat.2026.101071_bib40","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.135031","article-title":"Type I IFN response associated with mTOR activation in the TAFRO subtype of idiopathic multicentric Castleman disease","volume":"5","author":"Pai","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.modpat.2026.101071_bib41","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jare.2024.11.027","article-title":"miR-3606-3p alleviates skin fibrosis by integratively suppressing the integrin\/FAK, p-AKT\/p-ERK, and TGF-beta signaling cascades","volume":"75","author":"Chen","year":"2025","journal-title":"J Adv Res"},{"key":"10.1016\/j.modpat.2026.101071_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2025.140048","article-title":"Downregulation of collagen IV deposition and ITGB1-FAK signaling pathway to inhibit adipogenesis: a novel mechanism of swertiamarin in treating type 2 diabetes mellitus","volume":"299","author":"Chen","year":"2025","journal-title":"Int J Biol Macromol"},{"issue":"1","key":"10.1016\/j.modpat.2026.101071_bib43","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s13058-024-01942-2","article-title":"Cilengitide sensitivity is predicted by overall integrin expression in breast cancer","volume":"26","author":"Girnius","year":"2024","journal-title":"Breast Cancer Res"},{"issue":"10","key":"10.1016\/j.modpat.2026.101071_bib44","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.548","article-title":"Targeting integrin \u03b1v\u03b23 with indomethacin inhibits patient-derived xenograft tumour growth and recurrence in esophageal squamous cell carcinoma","volume":"11","author":"Liu","year":"2021","journal-title":"Clin Transl Med"},{"issue":"1","key":"10.1016\/j.modpat.2026.101071_bib45","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/neuonc\/noad148","article-title":"A disintegrin and metalloproteinase 22 activates integrin \u03b21 through its disintegrin domain to promote the progression of pituitary adenoma","volume":"26","author":"Xing","year":"2024","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.modpat.2026.101071_bib46","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3350\/cmh.2023.0343","article-title":"Protein-centric omics analysis reveals circulating complements linked to nonviral liver diseases as potential therapeutic targets","volume":"30","author":"Shi","year":"2024","journal-title":"Clin Mol Hepatol"},{"issue":"7","key":"10.1016\/j.modpat.2026.101071_bib47","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.devcel.2025.02.005","article-title":"Controlling pyroptosis through post-translational modifications of gasdermin D","volume":"60","author":"Zhang","year":"2025","journal-title":"Dev Cell"},{"issue":"6549","key":"10.1016\/j.modpat.2026.101071_bib48","doi-asserted-by":"crossref","DOI":"10.1126\/science.abg0269","article-title":"The lysosomal Rag-Ragulator complex licenses RIPK1 and caspase-8-mediated pyroptosis by Yersinia","volume":"372","author":"Zheng","year":"2021","journal-title":"Science"},{"issue":"21","key":"10.1016\/j.modpat.2026.101071_bib49","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202501535","article-title":"A site-specific photo-crosslinking proteomics approach provides insights into noncanonical pyroptotic caspase-4 substrates","volume":"64","author":"Zhou","year":"2025","journal-title":"Angew Chem Int Ed Engl"},{"issue":"9","key":"10.1016\/j.modpat.2026.101071_bib50","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/s41423-022-00905-x","article-title":"Role of pyroptosis in inflammation and cancer","volume":"19","author":"Wei","year":"2022","journal-title":"Cell Mol Immunol"},{"issue":"2","key":"10.1016\/j.modpat.2026.101071_bib51","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.cell.2024.11.018","article-title":"Transplantation of gasdermin pores by extracellular vesicles propagates pyroptosis to bystander cells","volume":"188","author":"Wright","year":"2025","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.modpat.2026.101071_bib52","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adi9284","article-title":"NU6300 covalently reacts with cysteine-191 of gasdermin D to block its cleavage and palmitoylation","volume":"10","author":"Jiang","year":"2024","journal-title":"Sci Adv"},{"issue":"1","key":"10.1016\/j.modpat.2026.101071_bib53","doi-asserted-by":"crossref","first-page":"7923","DOI":"10.1038\/s41467-023-43707-z","article-title":"Pyroptosis inhibiting nanobodies block gasdermin D pore formation","volume":"14","author":"Kopp","year":"2023","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.modpat.2026.101071_bib54","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41573-020-0071-y","article-title":"Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target","volume":"19","author":"Mifflin","year":"2020","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"10.1016\/j.modpat.2026.101071_bib55","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1182\/blood-2016-11-748855","article-title":"Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease","volume":"129","author":"Yu","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.modpat.2026.101071_bib56","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/art.43269","article-title":"Expert perspective: diagnosis and treatment of Castleman disease","volume":"78","author":"Chen","year":"2026","journal-title":"Arthritis Rheumatol"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395226001146?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395226001146?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T14:46:13Z","timestamp":1792075573000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395226001146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":56,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0893395226001146"],"URL":"https:\/\/doi.org\/10.1016\/j.modpat.2026.101071","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Integrated Bulk and Spatial Proteomics of Castleman Disease: Molecular Signatures Across Subtypes and Compartmentalized Pathogenic Networks in Idiopathic Multicentric Castleman disease (iMCD)\u2013Thrombocytopenia, Anasarca, Fever, Reticulin Fibrosis\/Renal Dysfunction, and Organomegaly (TAFRO)","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.modpat.2026.101071","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 THE AUTHORS. Published by Elsevier Inc. on behalf of the United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}],"article-number":"101071"}}